September 7, 2017 / 11:52 AM / in a year

BRIEF-‍Bristol-Myers Squibb says Opdivo plus Yervoy showed superior overall survival

Sept 7 (Reuters) - Bristol-Myers Squibb Co

* Checkmate-214 study evaluating Opdivo in combination with Yervoy stopped early for demonstrating overall survival benefit in patients with previously untreated advanced or metastatic renal cell carcinoma

* Combination of Opdivo and Yervoy also met secondary endpoint of improved overall survival in all randomized patients​

* Opdivo plus Yervoy showed superior overall survival versus current standard of care Sunitinib in intermediate- poor-risk patients

* Based on planned interim analysis, independent data monitoring committee recommended that trial be stopped early for Opdivo​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below